Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IVT Launching Cutting Balloon For Highly Resistant Coronary Artery Lesions

This article was originally published in The Gray Sheet

Executive Summary

InterVentional Technologies' Cutting Balloon microsurgical dilatation catheter system will be promoted to interventional cardiologists as either a primary, secondary or tertiary treatment for highly resistant coronary arterial lesions, the firm says.

You may also be interested in...



IVT CUTTING BALLOON IS NOT APPROVABLE BASED ON ANGIOPLASTY EQUIVALENCE DATA, FDA PANEL CONCLUDES; FIRM WILL CONTINUE RESTENOSIS REDUCTION STUDY

InterVentional Technologies plans to refocus on demonstrating the potential benefits of the Barath surgical dilatation balloon in reducing coronary artery restenosis as it continues clinical studies of the product. On March 4, FDA's Circulatory System Devices Panel unanimously (8-0) recommended against approval of the device, which is also known as the Cutting Balloon, based on data that attempted to show equivalence to standard balloon angioplasty for coronary artery dilatation.

QUOTED. 25 November 2020. Ricki Chase.

The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.

US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count

The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel